An Act to reduce the risks associated with allergic reactions
Do you support it?
Want to know if it passes?
We'll email you when H2503 moves — a committee vote, a floor vote, or a signature. Nothing else.
Free forever · unsubscribe in one click.
Your answer was recorded either way.
Which district are you in?
Your ZIP is all we need to match you to your own representatives — so we can tell you how they voted on H2503.
You're tracking H2503
We'll email you the moment it moves.
H2503 — An Act to reduce the risks associated with allergic reactions
No card. One bill, free forever — alerts when it moves.
-
1Introduced
-
2In Committee
-
3Passed House
-
4Passed Senate
-
5To Executive
-
6Enacted
This bill died with 194th General Court. It reached “Introduced” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.
Summary
An Act to reduce the risks associated with allergic reactions
Bill Text
- Full text Current
AI-generated reading aid from the bill's amendatory text — verify against the official bill.
The bill establishes regulations for businesses to provide and administer epinephrine auto-injectors for anaphylaxis, and grants liability protections to those involved.
-
Chapter 111 of the General Laws
Section 245. (a) Notwithstanding any general or special law to the contrary, the Department of Public Health shall promulgate regulations to allow businesses and other entities to be prescribed epinephrine auto-injectors for the purposes of: (1) providing an epinephrine auto-injector for immediate self-administration to any individual that an employee, designated individual, agent of the business, or other entity believes in good faith may be experiencing anaphylaxis, regardless of whether the individual has a prescription for an epinephrine auto-injector or has previously been diagnosed as being at risk of anaphylaxis due to an allergy; and (2) administering an epinephrine auto-injector to any individual by an employee, designated individual, or agent who has successfully completed the applicable training required by regulation in accordance with this section. (b) A business or other entity that possesses and makes available epinephrine auto-injectors in accordance with this section and its employees, designated individuals, and agents; an individual authorized to administer epinephrine auto-injectors pursuant to subsection (c); a health care professional that prescribes or dispenses epinephrine auto-injectors pursuant to this section; and a person who conducts the applicable training shall not be liable for any injuries or damages that result from any act or omission related to the administration or self-administration of an epinephrine auto-injector in accordance with this section that may constitute ordinary negligence. This immunity does not apply to acts or omissions constituting gross, willful, or wanton negligence. The administration of an epinephrine auto-injector in accordance with this section is not the practice of medicine. (c) Any business or other entity that possesses epinephrine auto-injectors pursuant to this section may make such epinephrine auto-injectors available to individuals other than those trained individuals described in subsection (a), and such individuals may administer such epinephrine auto-injectors to any individual believed in good faith to be experiencing anaphylaxis, if the epinephrine auto-injectors are stored in a locked, secure container and are made available only upon remote authorization by a licensed physician or nurse practitioner after consultation with the physician or nurse practitioner by audio, televideo, or other similar means of electronic communication. Consultation with a physician or nurse practitioner for this purpose shall not be considered the practice of telemedicine or otherwise be construed as violating any law or rule regulating the physician or nurse practitioner’s practice.
This adds a new section allowing businesses to handle and administer epinephrine auto-injectors while limiting their liability.
-
Chapter 111 of the General Laws
SECTION 2. (a) No later than 180 days following enactment, the department of public health shall adopt regulations necessary to carry out the provisions of this act. The regulations adopted shall: (1) Require each business or other entity that acquires epinephrine auto-injectors in accordance with this section to submit, on a form developed by the department, a report of each incident on the premises of the business or other entity involving a severe allergic reaction or the administration of an epinephrine auto-injector. (2) Provide for the development and publication of an annual report by the department compiling, summarizing, and analyzing all incident reports submitted pursuant to paragraph (1) of this section. (3) Establish detailed standards for training programs that must be completed by employees, designated individual, and agents of a business or other entity prior to administering an epinephrine auto-injector made available by the business or other entity. Such training shall be conducted by a licensed physician or nurse practitioner or by a nationally recognized organization experienced in training laypersons in emergency health treatment approved by the department. Training may be conducted online and, at a minimum, shall cover: (i) techniques on how to recognize symptoms of severe allergic reactions, including anaphylaxis; (ii) standards and procedures for the storage and administration of an epinephrine auto-injector; and (iii) emergency follow-up procedures.
This mandates the Department of Public Health to create regulations for training, reporting incidents, and compiling annual reports related to the administration of epinephrine auto-injectors.
-
Chapter 111 of the General Laws
SECTION 3. The department may establish a certification program to recognize a business or other entity has complied with the provisions of this act and maintains an allergy-friendly environment within which to work or visit.
This allows the Department to create a certification program for businesses that meet the new standards for an allergy-friendly environment.
Sponsors
- John Francis Moran · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 203 not signed on
Sponsors (1)
- John Francis Moran Democrat
Co-sponsors (0)
None.
Not signed on (203)
203 members have not signed on to this bill.
Show all 203 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does H2503 do?
- An Act to reduce the risks associated with allergic reactions
- Who sponsors H2503?
- H2503 is sponsored by John Francis Moran (Democrat).
- What is the current status of H2503?
- This bill died with 194th General Court. It reached “Introduced” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track H2503?
- Track H2503 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on H2503
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of H2503
Last checked for changes 4 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →